Results 261 to 270 of about 53,238 (282)
Some of the next articles are maybe not open access.
Selective Histone Deacetylase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry, 2012Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials.
Huili, Pan, Jiangying, Cao, Wenfang, Xu
openaire +2 more sources
Histone Deacetylase Inhibitors
2004The base sequence of DNA provides the genetic code for proteins. The regulation of expression or suppression of gene transcription is largely determined by the structure of the chromatin--referred to as epigenetic gene regulation (Agalioti et al., 2002; Jenuwein and Allis, 2001; Richards and Elgin, 2002; Spotswood and Turner, 2002; Zhang and Reinberg ...
Paul A, Marks +3 more
openaire +2 more sources
Histone Deacetylase Inhibitors
2021Histone Deacetylase Inhibitors (HDACi) inhibits deacetylases of histones and nonhistones. As such it has potential widespread biological effects. However, cancer cells are preferentially affected than normal cells making it a useful targeted therapy in cancer.
Opelo Sefhore, Silvia CW Ling
openaire +1 more source
Histone deacetylase inhibitors
Expert Opinion on Therapeutic Patents, 2007Sustained efforts towards identifying novel histone deacetylase (HDAC) inhibitors as suitable therapies for the treatment of cancer and other human diseases has been a goal for the pharmaceutical industry during the last decade. In the second half of 2006 these efforts culminated in the FDA granting approval for the first HDAC inhibitor ...
Steve Price, Hazel J Dyke
openaire +1 more source
Histone deacetylase inhibitor based prodrugs
European Journal of Medicinal Chemistry, 2020Histone deacetylases (HDACs) are a family of enzymes which play important roles in the development and progression of cancers. Inhibition of HDACs has been widely studied as a therapeutic strategy in the discovery of anticancer drugs. HDAC inhibitors (HDACIs) have exhibited potency against a variety of cancer types, and four of them have been approved ...
Wenli Fan +5 more
openaire +2 more sources
Histone deacetylase inhibitors: Anticancer compounds
The International Journal of Biochemistry & Cell Biology, 2009The reversible acetylation of proteins is mediated by histone acetyltransferases which acetylate proteins and histone deacetylases that remove the acetyl groups. High levels of histone acetylation are correlated with active genes, while hypoacetylation of histones corresponds with gene repression.
Karen T, Smith, Jerry L, Workman
openaire +2 more sources
Histone deacetylase inhibitors in lymphoma
Current Opinion in Oncology, 2010Although many advances have been made in the treatment of lymphoma in the past decade, the treatment of patients with relapsed and refractory disease remains challenging. Only a fraction of patients will be cured with salvage therapy and transplantation.
Amanda, Copeland +2 more
openaire +2 more sources
New patented histone deacetylase inhibitors
Expert Opinion on Therapeutic Patents, 2009Following FDA approval of vorinostat in 2006, several novel HDAC inhibitors (HDACis) have entered clinical trials, and there are numerous published patent applications claiming novel HDACis which were optimized as potential drug candidates, designed for regional or systemic release, and created as dual or multifunctional inhibitors.
Haishan, Wang, Brian W, Dymock
openaire +2 more sources
Histone deacetylase inhibitors: gathering pace
Current Opinion in Pharmacology, 2006Reversible histone acetylation is one of the key mechanisms involved in the epigenetic control of gene expression. A variety of recent studies has revealed a role for acetylation in a much broader repertoire of physiological processes, including proliferation control and protein folding, and has highlighted how a variety of non-histone regulatory ...
Nessa, Carey, Nicholas B, La Thangue
openaire +2 more sources
Anticancer activities of histone deacetylase inhibitors
Nature Reviews Drug Discovery, 2006Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression. In addition, the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.
Jessica E, Bolden +2 more
openaire +2 more sources